Keywords: Sanofi Pasteur, Sanofi-Aventis, Daiichi Sankyo, ActHIB, Flu vaccine, Japan
Sanofi/Daiichi Sankyo recall hemophilus flu vaccine ActHIB due to contamination
Article | 14 March 2011
French pharma major Sanofi-Aventis’ (Euronext: SAN) Japanese vaccines subsidiary and Japan’s second-largest drugmaker Daiichi Sankyo (TYO: 4568) have ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
